You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Robust Predictor of Breast Cancer Risk
SBC: Morgan and Mendel Genomics, Inc. Topic: NCISUMMARY Approximately 1.5 million women in the United States are at high-risk for developing breast cancer, based on inheritance of a germline mutation in a gene in the double strand-break (DSB) repair and cyclin-checkpoint pathways. Many are unaware of their genetic predispositions, because their family history is uninformative or unknown. Genetic testing is important for identifying mutations in ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety
SBC: VIRTUALLY BETTER INC Topic: NIMHDESCRIPTION provided by applicant Anxiety disorders are the most common psychiatric disorders among youth with lifetime prevalence ranging between of the general population Among anxiety disorders social anxiety disorder SAD affects of all youth resulting in significant short and long term impairment including increased likelihood of substance abuse limited academic achievemen ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel WEB Decision Support System for cardiac image interpretation and reporting
SBC: SYNTERMED INCORPORATED Topic: NHLBIDESCRIPTION (provided by applicant): Today's cardiac imaging field requires diagnosticians to master an ever-expanding knowledge base (KB) while the time to master this knowledge, apply it to specific tasks and reimbursement are steadily shrinking. These constraints pose a serious healthcare problem that inevitably leads to physician's errors. Thus new tools are required to assist physic ...
STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: 102Abstract The liver is the most common organ for metastasis of various cancersincluding pancreaticovariancolorectalgastric cancers and melanomaUveal melanoma metastasizes inof patients and upon metastasis targets the liver inof these casesThe most common primary malignant liver cancer worldwide is hepatocellular carcinomaHCCThe use of blind liver biopsy as a diagnostic tool for liver cancer has man ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NIAAAAbstract Chronic liver injury due to alcohol, metabolic dysfunction, viral hepatitis, or autoimmune disease results in liver inflammation and fibrosis. Liver fibrosis will progress to cirrhosis which is estimated to affect 1–2% of the world’s population. The major clinical consequences of cirrhosis are liver failure and hepatocellular carcinoma (HCC), both of which increase the risk of death. ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Robust Predictor of Colon Cancer Risk
SBC: Morgan and Mendel Genomics, Inc. Topic: 102Summary At least 500,000 people in the United States have Lynch syndrome (LS), based on inheritance of a genetic pathogenic variant in the mismatch repair (MMR) pathway, placing them at high-risk for colon and other cancers. More than half of them is unaware of their diagnosis, because their family history is uninformative or unknown. Genetic testing is important for identifying pathogenic variant ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of a protein drug for pancreatic cancer treatment
SBC: ProDa BioTech L.L.C. Topic: NCIAbstract Pancreatic cancers are devastating diseases with five year survival rate less thanCurrentlythere is no effective treatment for advanced diseaseOne major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal responseEvidence suggests that cancer associated pancreatic stellate cellsCAPaSCproduce the stromal collagenThe ECM laid down by CAPaSC is considered to be o ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health